A MultIceNTER Phase I Peptide VaCcine Trial to Exploit NeoePitope-Specific T Cells for the Treatment of H3-Mutated Gliomas – (INTERCEPT H3)
Phase 1
- Conditions
- glioma WHO grade IV (C71.1-9 according to ICD-10 classification)Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2024-514840-97-00
- Lead Sponsor
- Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method